September 07, 2021
2 min read
Source/Disclosures
Published by:
Disclosures:
The researchers report no relevant financial disclosures.
We were unable to process your request. Please try again later. If you…
Ligelizumab, omalizumab most effective in refractory chronic spontaneous urticaria
Source/Disclosures
